Fig. 1From: Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cellsHexagonal shaped single layer human endothelial corneal cells of donor corneas before (a, c, e, g) and after (b, d, f, h) incubation with 250 μg/ml ranibizumab (Lucentis®) or bevacizumab (Avastin®) at indicated magnifications. No statistical significant difference between before and after could be detectedBack to article page